FT: Amgen in the hunt for a $10B biotech buyout Print E-mail
By John Carroll - FierceBiotech   
Tuesday, 10 November 2015 02:57

Amgen is jumping back into the M&A game. And it's looking for another Onyx-sized deal that can deliver a late-stage drug ready to be hustled across the finish line.

The Financial Times reported this morning that Amgen's ($AMGN) management team has been briefing investors about its plans to buy another biotech for about $10 billion. That's what the big biotech paid for Onyx, which netted the cancer drug Kyprolis, and it's in the same ballpark asCelgene's $7.2 billion deal for Receptos.

That Receptos buyout inspired a fresh surge for Celgene's share price, pushing analysts to join in the chorus for more such deals from a lengthy lineup of big biotechs. Gilead ($GILD) as well as Biogen ($BIIB) have been quietly encouraging about buyout speculation, while Pfizer ($PFE) recently stepped up with a new megamerger pitch for Allergan ($ACT).

 

READ MORE HERE




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter